European Journal Of Cancer SCIE

國際簡稱：EUR J CANCER 參考譯名：歐洲癌癥雜志

主要研究方向：腫瘤學-醫(yī)學非預警期刊審稿周期：約1.0個月約5.3周

《歐洲癌癥雜志》(European Journal Of Cancer)是一本由Elsevier Ltd出版的以腫瘤學-醫(yī)學為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時報道該領(lǐng)域相關(guān)理論、實踐和應用學科的最新發(fā)現(xiàn)，旨在促進該學科領(lǐng)域科學信息的快速交流。該期刊是一本開放期刊，近三年沒有被列入預警名單。該期刊享有很高的科學聲譽，影響因子不斷增加，發(fā)行量也同樣高。

1區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
318 年發(fā)文量
7.6 IF影響因子
開放是否OA
193 H-index
1990 創(chuàng)刊年份
Semimonthly 出版周期
English 出版語言

The European Journal of Cancer (including EJC Supplements), is an international comprehensive oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), translational oncology, and on cancer epidemiology and prevention. The Journal now has online submission for authors.

[ 查看全部 ]

投稿咨詢加急咨詢

European Journal Of Cancer期刊信息

ISSN：0959-8049
出版語言：English
是否OA：開放
E-ISSN：1879-0852
出版地區(qū)：ENGLAND
是否預警：否
出版商：Elsevier Ltd
出版周期：Semimonthly
創(chuàng)刊時間：1990
開源占比：0.3075
Gold OA文章占比：39.56%
OA被引用占比：0.2544...
出版國人文章占比：0.02
出版撤稿占比：0
研究類文章占比：90.25%

European Journal Of Cancer CiteScore評價數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

11.5

2.501

1.994

學科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Oncology	Q1	47 / 404	88%
大類：Medicine 小類：Cancer Research	Q1	40 / 230	82%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個指標。當年CiteScore 的計算依據(jù)是期刊最近4年（含計算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻數(shù)。例如，2022年的 CiteScore 計算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻數(shù)量注：文獻類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。

European Journal Of Cancer中科院評價數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	1區(qū)	ONCOLOGY 腫瘤學	2區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	1區(qū)	ONCOLOGY 腫瘤學	2區(qū)

中科院 2021年12月舊的升級版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	1區(qū)	ONCOLOGY 腫瘤學	2區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	1區(qū)	ONCOLOGY 腫瘤學	2區(qū)

中科院 2021年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	1區(qū)	ONCOLOGY 腫瘤學	2區(qū)

中科院 2020年12月舊的升級版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	1區(qū)	ONCOLOGY 腫瘤學	2區(qū)

European Journal Of Cancer JCR評價數(shù)據(jù)（2023-2024年最新版）

按JIF指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：ONCOLOGY	SCIE	Q1	38 / 322	88.4%

按JCI指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：ONCOLOGY	SCIE	Q1	34 / 322	89.6%

European Journal Of Cancer歷年數(shù)據(jù)統(tǒng)計

影響因子

中科院分區(qū)

European Journal Of Cancer中國學者發(fā)文選摘

1、KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer
Author: Xu, Jianming; Ying, Jieer; Liu, Rongrui; Wu, Jun; Ye, Feng; Xu, Nong; Zhang, Yanqiao; Zhao, Rusen; Xiang, Xiaojun; Wang, Jianhong; Lin, Xiaoyan; Xu, Huiting; Gao, Shegan; Luo, Suxia; Guo, Baohong; Li, Xionghui; Su, Yangzhi; Wang, Qian

Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 1-12. DOI: 10.1016/j.ejca.2022.10.004
2、Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer
Author: Swain, Sandra M.; Tan, Antoinette R.; Gianni, Luca; Kuemmel, Sherko; Dang, Chau T.; Schneeweiss, Andreas; O'Shaughnessy, Joyce; Liu, Haiying; Aguila, Christian; Heeson, Sarah; Macharia, Harrison; Yang, Ke; Restuccia, Eleonora; Loibl, Sibylle

Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 70-81. DOI: 10.1016/j.ejca.2022.09.024
3、Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)
Author: Sheng, Xinan; Ye, DingWei; Zhou, Aiping; Yao, Xin; Luo, Hong; He, Zhisong; Wang, Zengjun; Zhao, Yingchao; Ji, Zhigang; Zou, Qing; He, Chaohong; Guo, Jianming; Tu, Xinhua; Liu, Ziling; Shi, Benkang; Liu, Ben; Chen, Peng; Wei, Qiang; Hu, Zhiquan; Zhang, Yanqiao; Jiang, Kui; Zhou, Fangjian; Wu, Dapeng; Fu, Cheng; Li, Xingya; Wu, Bin; Wang, Lijie; Qin, Shukui; Li, Gang; Liu, Yunpeng; Guo, Hongqian; Chen, Kehe; Zhang, Dahong; Wang, Gongxian; Ding, Lieming; Wang, Yang; Yuan, Xiaobin; Guo, Jun

Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 205-215. DOI: 10.1016/j.ejca.2022.10.025
4、Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
Author: Guo, Ye; Zhang, Weijie; Ying, Jieer; Zhang, Yanqiao; Pan, Yueyin; Qiu, Wensheng; Fan, Qingxia; Xu, Qi; Ma, Yue; Wang, Gang; Guo, Jing; Su, Weiguo; Fan, Songhua; Tan, Panfeng; Wang, Yan; Luo, Yang; Zhou, Hui; Li, Jin

Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 181, Issue , pp. 26-37. DOI: 10.1016/j.ejca.2022.12.004
5、Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
Author: Cueva, Juan F.; Palacio, Isabel; Churruca, Cristina; Herrero, Ana; Pardo, Beatriz; Constenla, Manuel; Santaballa, Ana; Manso, Luis; Estevez, Purificacin; Maximiano, Constanza; Legeren, Marta; Marquina, Gloria; de Juan, Ana; Quindos, Maria; Sanchez, Luisa; Barquin, Arantzazu; Fernandez, Isaura; Martin, Cristina; Juarez, Asuncin; Martin, Teresa; Garcia, Yolanda; Yubero, Alfonso; Gallego, Alejandro; Bueno, Alejandro Martinez; Guerra, Eva; Gonzalez-Martin, Antonio

Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 182, Issue , pp. 3-14. DOI: 10.1016/j.ejca.2022.12.023
6、Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial
Author: Wang, Xuan; Wu, Xiaowen; Yang, Yue; Xu, Weiran; Tian, Hui; Lian, Bin; Chi, Zhihong; Si, Lu; Sheng, Xinan; Kong, Yan; Zhou, Li; Mao, Lili; Li, Siming; Tang, Bixia; Yan, Xieqiao; Bai, Xue; Guo, Jun; Cui, ChuanLiang

Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 182, Issue , pp. 57-65. DOI: 10.1016/j.ejca.2022.12.027
7、First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
Author: Reck, Martin; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Schenker, Michael; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Felip, Enriqueta; Juan-Vidal, Oscar; Alexandru, Aurelia; Cheng, Ying; Sakai, Hiroshi; Paz-Ares, Luis; Lu, Shun; John, Thomas; Sun, Xiaowu; Moisei, Aniela; Taylor, Fiona; Lawrance, Rachael; Zhang, Xiaoqing; Sylvester, Judi; Yuan, Yong; Blum, Steven I.; Penrod, John R.; Carbone, David P.

Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 183, Issue , pp. 174-187. DOI: 10.1016/j.ejca.2023.01.015
8、OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Author: Robson, Mark E.; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Tung, Nadine; Armstrong, Anne; Dymond, Mike; Fielding, Anitra; Allen, Allison; Conte, Pierfranco

Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 184, Issue , pp. 39-47. DOI: 10.1016/j.ejca.2023.01.031